Study Design. Randomized, controlled pilot trial.
T he proper control of acute and chronic pain is one of the most important areas in health care. Despite profound advances in neuroscience over the past 20 years, we still largely use opiate narcotics for pain control. Lumbar spinal surgery is a common orthopedic procedure, and while back and leg pain are often complaints that precede surgery, the procedures themselves are associated with considerable postoperative pain lasting days to weeks. Adequate postoperative pain control is an important factor in determining recovery time and hospital length of stay. Systemic opioid analgesics have associated side-effects that can lead to postoperative complications including but not limited to mental-clouding, confusion, addiction (in some cases), respiratory depression, interactions with other medications, and fatigue. These are not trivial concerns as patients receiving orthopedic and spinal surgeries are likely to be older or overweight, or both, and thus these complications can have serious negative consequences.
New analgesic strategies are needed that can be used adjunctively to existing strategies with the potential to reduce reliance on opioid analgesia. Several novel brain stimulation technologies including transcranial direct current stimulation (tDCS) are beginning to demonstrate promise as treatments for a variety of pain conditions. [3] [4] [5] [6] Electricity has no metabolite or other residue, and can be delivered with minimal discomfort and without problems associated with drug-drug interactions. In two preliminary studies, the investigators have found that tDCS can reduce postoperative patient-controlled analgesia (PCA) use by as much as 46% in total knee arthroplasty patients while simultaneously reducing subjective pain ratings. However, more work needs to be done to verify whether these effects are real and whether tDCS might be useful across different surgical procedures. The present study is the first randomized, double-blind, sham-controlled pilot clinical trial of tDCS for pain and PCA opioid usage among patients receiving spine surgery.
MATERIALS AND METHODS

Participants
Twenty-seven patients undergoing lumbar spine procedures at Medical University of South Carolina that required at least one-night hospitalization for parenteral pain medication were enrolled in the present study. Approval from the Institutional Review Board was obtained prior to the initiation of the study and written informed consent was obtained from each subject prior to any surgical procedures.
Postoperative Care and Pain Measurement
Postoperative orders included a standardized protocol for self-administered PCA hydromorphone. Initial PCA settings consisted of hydromorphone 0.2 mg/dose with a lockout interval of 10 minutes. The 4-hour maximum dose was 4.8 mg with no continuous infusion. PCA pump usage was downloaded from the PCA pump after discharge from the hospital. Patient pain ratings were collected via three items from the Brief Pain Inventory (BPI) at the time of admission and discharge. Participants were asked to rate their ''pain at its least,'' ''pain on average,'' and ''pain at its worst'' during the previous 24 hours using the standard 11-point numeric rating scale (NRS) from the BPI.
tDCS Methods
Immediately after surgery, participants were randomly assigned to receive 20 minutes of real or sham tDCS (2 mA, anode placed over the superior motor cortex (corresponding to the low-back/trunk area) and cathode over the right dorsolateral prefrontal cortex). tDCS was delivered using the Chattanooga Ionto device (DJO UK Ltd, Guildford Surrey, UK). Electrode placement was determined using the EEG 10-20 system (positions Cz and F4). To ensure blinding, specially designed software was utilized to switch the tDCS on and off without any intervention from the patient or experimenters. This was controlled via a silent solid-state relay driven by an Ontrak ADU218 (Ontario, Canada). For sham tDCS, the stimulator was turned off automatically after 45 seconds, whereas real tDCS involved stimulation for 20 minutes. The initial sham stimulation mimics the transient scalp sensation that is perceived when the stimulator is initially switched on. The treatment type (real vs. sham) was encoded in the controller software so that the tDCS administrator only entered a patient number to start stimulation without knowing whether those specific numbers were associated with active or sham tDCS. Four sessions of tDCS (all real or all sham) were administered (Session 1-approximately 30 minutes after surgery, Session 2-4 hours later, Session 3-on the morning of postoperative day-1, and Session 4-4 hours later). To monitor for adverse events directly associated with tDCS, participants were asked to report any sensations they experienced during each of the four tDCS stimulation sessions at 1-minute, 10-minutes, and 20-minutes into the sessions.
Statistical Analysis
Linear mixed modeling was applied to examine the slopes of cumulative PCA medication usage curves between groups (unstructured covariance matrix and restricted maximum likelihood). For secondary outcomes, independent t tests were applied to examine between-group (real vs. sham tDCS) differences in NRS pain ratings. Within subject t tests were applied to examine change in NRS pain ratings from admission to discharge, and the x 2 test was used to evaluate participant correct-guess rates regarding treatment assignment (real vs. sham).
RESULTS
Twenty-seven patients were enrolled in and completed this pilot study before the study was closed due to funding expiration. The mean age of the patients was 59.4 years (SD ¼ 2.1) and 10 were men. Fifteen percent were African American and 85% were Caucasian. Thirty-three percent underwent fusion procedures, 26% decompression, 15% herniated disc repair, 15% laminectomy, and 11% hardware revision procedures. The mean duration of surgery was 3.4 hours (SD ¼ 1.2). Forty-six percent of patients were on chronic opioid therapy for pain at the time of admission, and the mean NRS average-pain rating of the sample was 6.6 (SD ¼ 1.5) of 10 at the time of admission. Fourteen participants were randomized to receive real tDCS and 13 received sham. There were no differences between the real and sham tDCS groups at baseline with respect to age, chronic opioid therapy status, pain at its worst, pain at its least, pain on average, weight, or sex (see Table 1 ). No adverse events were observed with the tDCS. Side effects of tDCS were very mild, generally rare and tended to decline throughout each session. Sensations reported at 1-, 10-, and 20-minute time points during each of the four tDCS sessions included: pressure from the elastic bands, itching under the electrodes, tingling, burning, pain, warmth, and stinging. The most common reported sensation was ''tingling'' which occurred in as high as 26% of the sample during the first minute of Table 2 ).
RANDOMIZED TRIAL
The effect of tDCS (real vs. sham) on the slope of the cumulative PCA hydromorphone curve was significant (F(238,2879) ¼ 5.06, P < 0.001; see Figure 1 ). At the time of discharge, participants who received real tDCS used an average of 12.6 mg (SD ¼ 9.9) of hydromorphone and subjects receiving sham tDCS used an average of 16.5 mg (SD ¼ 12.7) suggesting that tDCS was associated with a 23% reduction in PCA usage (effect-size Cohen's d ¼ 0.3). Participants were unable to correctly guess whether they received real or sham tDCS at a rate better than chance (52% correct guess rate; P ¼ 0.84, ns).
Independent t test analysis of NRS scores from the BPI at admission and discharge indicated no significant differences between tDCS groups at admission for pain on average, pain at its least, or pain at its worst (P ¼ 0.24, P ¼ 0.22, P ¼ 0.27, respectively) nor at discharge (P ¼ 0.58, P ¼ 0.47, P ¼ 0.72). In the real tDCS group a significant 31% reduction was observed in pain-at-its-least ratings from admission (mean ¼ 4.5 SD ¼ 2.5) to discharge (mean ¼ 3.2 SD ¼ 2.2; t(12) ¼ 2.52, P ¼ 0.027), but no other changes in pain ratings were significant in either group.
DISCUSSION
The present pilot trial is the first study to demonstrate an opioid-sparing effect of tDCS after spine surgical procedures. The effect-size observed (d ¼ 0.3) is ''medium'' in magnitude and significant improvement in pain-at-itsleast was observed in the active tDCS group.
tDCS involves the application of low-intensity (usually 2 mA) electrical current to the cortex. 7 tDCS has been developed as a clinical tool for the modulation of brain activity and typically uses saline-soaked electrodes that are applied to the scalp over targeted brain areas to deliver a weak constant current. 8 Recent studies suggest that tDCS is more effective than sham stimulation at reducing pain in fibromyalgia and pain due to spinal cord injury. 9, 10 When managing pain with tDCS, the goal is to modulate activity in the areas of the brain that are involved in pain processing. tDCS with the anode placed over a cortical target results in a raised level of excitability under the electrode, whereas cathodal stimulation appears to decrease local cortical excitability.
11
Pain is a complex experience that has sensory-discriminatory, motivational-affective, and cognitive-evaluative dimensions. 12 Experimental and clinical fMRI findings suggest that parietal areas, including the primary somatosensory cortex, are mainly involved in the sensory-discriminative dimension of pain experience and frontolimbic networks are involved in the affective dimension. 13, 14 Activation of somatosensory cortex tends to be limited to activation contralateral to the side of stimulation, whereas secondary somatosensory cortex activation tends to 19%  4%  7%  7%  4%  7%  11%  11%  7%  7%  7%  4% Itching
demonstrate bilateral activation. 15, 16 There is evidence supporting the involvement of the anterior cingulate cortex in the affective dimension of pain experience. 13, 14, 17, 18 Other brain structures that appear to be involved in the affective component of pain experience include the lateral and medial thalamus, insular cortex, and the prefrontal cortex. [19] [20] [21] [22] The role of the left prefrontal cortex in pain control is unclear. However, there is evidence to support the concept that left prefrontal activation is negatively correlated with pain unpleasantness 23 suggesting a possible governing role of the left prefrontal cortex on the affective dimension of pain experience. 24 There is evidence that activation of the left prefrontal cortex is associated with analgesic effects, presumably by modulating limbic response to pain. There is also evidence that deactivation of the right prefrontal cortex is associated with improvement in clinical pain 25 suggesting a distinct laterality with respect to the role(s) of the prefrontal cortex in pain modulation. However, imaging studies and numerous cortical stimulation studies in humans suggest that motor cortex stimulation can significantly reduce pain as well by modulating activity in networks of brain areas involved in pain processing, such as the thalamus and by facilitating descending pain inhibitory mechanisms. [26] [27] [28] In the present study, tDCS was presumably used to activate motor cortex (anode) while deactivating the right prefrontal cortex (cathode), thereby modulating pain circuitry and perception after surgery.
Little work has been published studying any form of electrical treatment for postoperative pain after spine surgery. Martelete and Fiori 29 compared transcutaneous electrical stimulation, electroacupuncture and intravenous Meperidine in patients undergoing a number of different procedures, including lumbar surgery. They found both forms of electrical treatment to be superior to Meperidine alone. 29 In a canine study, Laim et al 30 found lower usage of narcotics for the initial 12 hours after thoracolumbar surgery in patients who received electroacupuncture although the results of this study may be difficult to extrapolate to a human population. While our group has found opioid sparing and analgesic effects of TMS and tDCS in post-bariatric-surgery patients, post-total-knee-arthroplasty patients, and post-ERCP patients, to the best of our knowledge, this is the first study to evaluate tCDS for postoperative pain in lumbar surgery patients.
Weaknesses of this pilot study include the small samplesize, heterogeneous surgical sample, and short follow-up period. However, despite these limitations, a moderate effect-size was observed for tDCS, suggesting that future work in this area is warranted.
Overall, the present study suggests that tDCS stimulation after lumbar spine procedures has the potential to decrease the amount of narcotic required for pain control and more studies are needed to better characterize the effects of tDCS on postsurgical pain.
Key Points
Brain stimulation using tDCS reduces postsurgical opioid consumption. tDCS may reduce subject pain ratings. tDCS is minimally invasive and might be a viable adjunctive postoperative pain management strategy.
